- Home
- AZ vs CRBP Comparison
AZ vs CRBP Comparison
Compare AZ & CRBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AZ | CRBP |
|---|---|---|
| Founded | 2018 | 2009 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 224.3M | 170.3M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | AZ | CRBP |
|---|---|---|
| Price | $5.56 | $9.60 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 8 |
| Target Price | $20.00 | ★ $50.29 |
| AVG Volume (30 Days) | 485.6K | ★ 513.0K |
| Earning Date | 11-13-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $7,463,000.00 | N/A |
| Revenue This Year | $1,343,857.60 | N/A |
| Revenue Next Year | N/A | $100.00 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 41.45 | N/A |
| 52 Week Low | $5.00 | $4.64 |
| 52 Week High | $12.36 | $20.56 |
Technical Indicators
Market Signals| Indicator | AZ | CRBP |
|---|---|---|
| Relative Strength Index (RSI) | 40.04 | 32.96 |
| Support Level | $5.61 | $9.44 |
| Resistance Level | $6.85 | $11.64 |
| Average True Range (ATR) | 0.59 | 0.73 |
| MACD | -0.04 | -0.03 |
| Stochastic Oscillator | 10.62 | 4.33 |
Price Performance
Historical ComparisonAbout AZ A2Z Smart Technologies Corp.
A2Z Cust2Mate Solutions Corp is engaged in creating shopping carts. With the help of a user-friendly smart algorithm, touch screen, and other technologies, the company streamlines the retail shopping experience by scanning purchased products and enabling in-cart payment so that customers can simply pick & go, and bypass long cashier checkout lines.
About CRBP Corbus Pharmaceuticals Holdings Inc.
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.